Filing Flows › Xilio Therapeutics (XLO) › Q2 2026
Xilio Therapeutics (XLO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Xilio Therapeutics (XLO) reported revenue of $18.7M for the second quarter 2026 (Q2 2026), +131% from a year earlier and +48% from the quarter before. Operating margin was -18.7%, net loss $6.4M (34.1% of revenue).
Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%, net loss $6.4M, operating cash flow −$18.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.7M | +48% | +131% |
| Operating profit | −$3.5M | — | — |
| Net earnings | −$6.4M | — | — |
| Operating cash flow | −$18.8M | — | — |
What changed
Revenue was $18.7M in Q2 2026, up 131% year over year and up 48% from the previous quarter.
Operating costs exceeded revenue by $3.5M, an operating margin of -18.7%. Total costs fell 1% while revenue rose 131%. The quarter ended with a net loss of $6.4M, narrower than the previous quarter's $9.5M loss.
Operating cash flow was −$18.8M. Non-cash charges added back $331K of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $14.3M. Capital expenditures of $19K exceeded it, leaving free cash flow of −$18.8M.
Questions
What was Xilio Therapeutics' revenue in the second quarter 2026?
Xilio Therapeutics (XLO) reported revenue of $18.7M for the second quarter 2026 (Q2 2026), +131% from a year earlier and +48% from the quarter before.
Was Xilio Therapeutics profitable in the second quarter 2026?
Operating loss was $3.5M (-18.7% of revenue) and net loss $6.4M.
Source: Xilio Therapeutics 10-Q on SEC EDGAR.